Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

Merck (MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...

The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

The World Health Organization raises alarms over increased West Bank violence affecting healthcare. In Congo, over 50 die due ...

Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles.

Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma ...

The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of its cancer drugs against Keytruda.

Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...